

Original Research Paper

Vaccination and Immunization Misconceptions in Cameroon: An Appraisal

Ndipowa James Attangeur Chimfutumba^{1*}, Yongabi Kenneth Anchang² and Dismas Ongore³

¹Faculty of Medicine and Biomedical Sciences, Cameroon Christian University, Bali, Cameroon.

²Phybiototechnology Research Foundation Institute, Catholic University of Cameroon, Bamenda, Cameroon.

³School of Public Health, University of Nairobi, Nairobi, Kenya.

Accepted 20th July, 2016.

For several decades, Cameroon has been experiencing massive challenges with regards to infection prevention and the fight against epidemics. The resistance against and refusal of vaccines by some populations has marred the efficiency and efficacy of vaccination campaigns against diseases of epidemic potential such as Measles, Yellow Fever, Tetanus, Poliomyelitis, etc. This phenomenon has been observed in many regions of Cameroon, particularly the North West, Litoral, Centre, East and West Regions of the country. In 1990, there was massive refusal of the Tetanus Toxoid vaccine (TT), followed by the refusal of the Human Papillomavirus Vaccine (HPV), and the persistent refusals of the Poliomyelitis Vaccine by some families and communities. Very recently there has been massive anti-campaigns leading to the boycott of the Ebola Trial Vaccine in Bamenda and Yaoundé. Effective vaccination and immunization coverage in Cameroon, therefore, needs to be reviewed.

Keywords: Vaccination, Immunization, Misconception, Appraisal, Cameroon.

INTRODUCTION

Throughout the world, childhood immunization is a major public health intervention for preventing disease and mortality. Although the vaccination coverage in most high-income countries is significantly high, variations in coverage rates on the national level among different ethnic backgrounds are reported [19].

This phenomenon is more common in low-income settings such as Cameroon where infection prevention and the fight against infectious diseases and epidemics is quasi-difficult to handle. Efficient and effective vaccination campaigns constitute an essential and sustainable strategy of overcoming this phenomenon in order to curb the rising morbidity and mortality rates among local populations.

In the Netherlands, for example, the overall vaccination coverage among newborns is 95 %. The vaccination coverage among young adolescent girls against cervical cancer caused by Human Papilloma Virus (HPV), is 59 %. The National Immunization Programme (NIP) is coordinated by the National Institute for Public Health and the Environment. The National Immunization Programme targets 12 diseases (polio, diphtheria, tetanus, pertussis, rubella, measles, mumps, disease caused by *Haemophilus Influenzae* type b, meningococcal C disease, hepatitis B, pneumococcal disease and cervical cancer caused by HPV). It is non-mandatory, and

free of charge [19]. Some health districts in certain regions of Cameroon have a huge challenge to grapple with this phenomenon, the reason why vaccination and immunization in Cameroon are generally quite difficult to grapple with.

THE CAMEROON VACCINATION BACKGROUND

For more than two decades Cameroon has been experiencing serious challenges with regards to infection prevention and the fight against epidemics. The resistance towards and refusal of vaccination registered by some populations has marred the efficiency and efficacy of vaccination and immunization campaigns against diseases of epidemic potential such as Measles, Yellow Fever, Poliomyelitis, Hepatitis B, and Meningitis, etc.

The resistance towards and refusal of vaccination has been a common phenomenon in some regions, particularly in the North West, Litoral, Centre, East and West Regions. This is aggravated by the periodic stock outs of some vaccines such as BCG in the Northern, Centre and North West Regions of the country. It would be very interesting to make a brief appraisal of the failures and successes of the National Polio Vaccination campaign in the North West Region of Cameroon just at having a view of the following pictures below.

*Corresponding Author: Ndipowa James Attangeur Chimfutumba. Cameroon Christian University, P.O. Box 5, Bali, North West Region, Cameroon.
Email: ndipowajames@gmail.com



Picture 1



Picture 2



Picture 3

NB: Pictures 1 and 2: The devastating effects of polio still noticed in some remote and very poorly accessed villages. Some of these orthopaedic anomalies are being provided supportive physiotherapy by the use of wooden crutches in a Catholic Health Centre at Mambu-Bafut in the North West Region of Cameroon. **Picture 3:** Recent suspected case of AFP in an Under-Five living with the grandmother in Sob, Kumbo East, still under confirmative investigation (2015 pictures).

In 1990 the North West population boycotted the Tetanus Toxoid vaccination campaigns meant for women of childbearing age, intended to fight against neonatal tetanus. This was motivated by political rumors and misconceptions that “the Tetanus Toxoid was meant to render the women of childbearing age infertile as a means of reducing the population of the opposition political parties”. This inevitably had a very devastating effect on government efforts in the prevention of neonatal tetanus. From this premise, it would be very useful to have a nutshell review of the diseases in question.

In brief, Tetanus, also known as lockjaw, is an infection characterized by muscle spasms. In the most common type, the spasms begin in the jaw and then progress to the rest of the body. These spasms usually last a few minutes each time and occur frequently for three to four weeks.[1] Spasms may be so severe that bone fractures may occur.[2] Other symptoms may include fever, sweating, headache, trouble swallowing, high blood pressure, and a fast heart rate.[1][2] The onset of symptoms is typically three to twenty-one days following infection. It may take months to recover. About 10% of those infected die.[1]

Infection can be prevented by proper immunization with the tetanus vaccine. In those who are infected tetanus immune globulin or if not available intravenous immunoglobulin (IVIG) is used. Tetanus occurs in all parts of the world but is most frequent in hot and wet climates where the soil contains a lot of organic matter.[1] In 2013 it caused about 59,000 deaths – down from 356,000 in 1990.[5]

There is neonatal tetanus which is a form of generalized tetanus that occurs in newborns, usually those born to mothers who themselves have not been vaccinated. If the mother has been effectively vaccinated against tetanus, the infants acquire passive immunity and are thus protected for some time.[10] It usually occurs through infection of the unhealed umbilical stump, particularly when the stump is separated with a non-sterile instrument. As of 1998, neonatal tetanus was common in many developing countries and was responsible for about 14% (215,000) of all neonatal deaths.[11] In 2010 the worldwide death toll was 58,000 newborns.

As the result of a public health campaign, the death toll from neonatal tetanus was reduced by 90% between 1990 and 2010, and by 2013 the disease had been largely eliminated from all but 25 countries in the world.[12] Neonatal tetanus is rare in developed countries. In neonatal tetanus, symptoms usually appear from 4 to 14 days after birth, averaging about 7 days. The fatality rate for infants has been estimated as 70% to 100% and death usually occurs by the age of 2 weeks.[2] The time from exposure to symptoms may be up to several months.[4]

The spores which cause tetanus are present everywhere, so the only prevention is immunization. Three properly spaced doses of tetanus toxoid vaccine are recommended for women of childbearing age, either before or during pregnancy. This will protect their future babies from neonatal tetanus after delivery.[2]

Adequate immunization by routine boosters in non-pregnant women of childbearing age can obviate the need to vaccinate women during pregnancy. Therefore women of childbearing age ought to be systematically and effectively vaccinated against tetanus without prejudice. Soon after Tetanus Toxoid misconception, the Human Papilloma Vaccine (HPV) meant for the prevention of cancer suffered the same fate in parts of the North West and Centre Regions of Cameroon.

It is worth understanding that the Human Papilloma Vaccine (HPV) is named for the warts (papilloma) some HPV types can cause. Some other HPV types can lead to cancer, especially cervical cancer. There are more than 40 HPV types that can infect the genital areas of males as well as females. But there are vaccines that can prevent infection with the most common types of HPV.

HPV is transmitted through intimate skin-to-skin contact. You can get HPV by having vaginal, anal, or oral sex with someone who has the virus. It is most commonly spread during vaginal or anal sex. HPV is the most common sexually transmitted infection (STI). Anyone who is sexually active can get HPV, even if you have had sex with only one person. HPV can be passed even when an infected person has no signs or symptoms. One can develop symptoms years after having sex

with someone who is infected, making it hard to know when one first became infected. Every year, over 27,000 women and men are affected by cancer caused by HPV— that is, a new case every 20 minutes. [17]

Persistent HPV infection can cause various types of cancer including:

- Cervical cancer: The most common HPV cancer. Almost all cervical cancer is caused by HPV.
- Vulvar cancer: About 69% are linked to HPV.
- Vaginal cancer: About 75% are linked to HPV.
- Penile cancer: About 63% are linked to HPV.
- Anal cancer: About 91% are linked to HPV.
- Cancer of the back of the throat: About 72% are linked to HPV. [Note: Many of these cancers may also be related to tobacco and alcohol use]

Most of these cancers could be prevented by HPV vaccination at ages 11-12. The human papillomavirus (HPV) vaccines are safe, effective, and offer long-lasting protection against cancers caused by HPV [17][4].

Each HPV vaccine—Gardasil® 9, Gardasil®, and Cervarix®—went through years of extensive safety testing before they were licensed by the U.S. Food and Drug Administration (FDA). Gardasil® 9 was studied in clinical trials with more than 15,000 females and males; Gardasil® was studied in clinical trials with more than 29,000 females and males, and Cervarix® was studied in trials with more than 30,000 females.

Research from before and after the vaccines were licensed show that HPV vaccines are safe. As with all approved vaccines, CDC and the FDA closely monitor the safety of HPV vaccines after they are licensed. Any problems detected with these vaccines will be reported to health officials, health care providers, and the public. [4][29]

Like any vaccine or medicine, HPV vaccines can cause side effects. The most common side effects are pain, redness, or swelling in the arm where the shot was given; dizziness, feeling of fainting, nausea, and headache. HPV vaccination is typically not associated with any serious side effects. The benefits of HPV vaccination far outweigh any potential risk of side effects.

Despite the availability of information and literature published on this very important subject, in November 2015, a boycott was staged in Bamenda and Yaoundé against the testing of the Ebola Trial Vaccine virtually for the same type of rumors and misconceptions. Meanwhile, in the Bamenda Regional Hospital, some 171 clients had already been scrupulously screened and counseled before being given the trial vaccine, while in Yaoundé 8 clients had gone through the same process before the boycott was staged. Despite the boycott the Ministry of Public Health kept its word and was scrupulously following up all the volunteers who had gone in for the trial vaccine. Up till now, Cameroon has not experienced any outbreak of Ebola Viral disease yet, but her closest neighbor, Nigeria, has. Nevertheless, Cameroon is strategically located in Africa with a geographical setting, disease determinants and behavioral patterns that are very similar to those of all the other Ebola-infected countries.

Ebola viral disease, hitherto known as Ebola hemorrhagic fever, is a very severe, highly infectious (contagious) and fatal zoonotic illness in humans with a case fatality rate of about 90%. There is a lot of literature about this disease in various related domains but the most important component is how to handle and cope with it practically. Infected patients require

strategic and intensive nursing and supportive care since, as at now, there is neither a licensed specific treatment nor a vaccine for use in both humans and animals [26][27].

According to current literature and statistics, Ebola vaccine trial proves 100% successful in Guinea. The rVSV-ZEBOV candidate vaccine uses a vesicular stomatitis virus carrying a non-infectious Ebola virus gene. The vaccine cannot cause Ebola viral disease but can potentially stimulate an immune response to protect against the disease. The vaccine was developed by the Public Health Agency of Canada's National Microbiology Laboratory and licensed to New Link Genetics. In 2014, New Link Genetics entered into a licensing and collaboration agreement with Merck to research, develop, manufacture, and distribute the rVSV-ZEBOV candidate vaccine.

The vaccine has, and continues to be, studied in hundreds of people (as of March 26, 2015, more than 800 people) in Africa, Canada, Europe, and the United States. Results from early studies to date of the vaccine show an acceptable safety profile and indicate that the rVSV-ZEBOV candidate vaccine produces an immune response. The Biomedical Advanced Research and Development Authority is supporting the advanced development and manufacturing of the vaccine and is assisting CDC in conducting the clinical trial in Sierra Leone. The first trial of an Ebola vaccine in Africa started with the vaccination of three health care workers in Mali [26][27][28].

According to Sarah Boseley, Health editor, Friday 31 July 2015 at 16.44 BST Last modified on Saturday 1 August 2015, 00.02 BST, "A vaccine against Ebola has been shown to be 100% successful in trials conducted during the outbreak in Guinea and is likely to bring the west African epidemic to an end, experts say. The results of the trials involving 4,000 people are remarkable because of the unprecedented speed with which the development of the vaccine and the testing were carried out. Scientists, doctors, donors and drug companies collaborated to race the vaccine through a process that usually takes more than a decade in just 12 months".

"Having seen the devastating effects of Ebola on communities and even whole countries with my own eyes, I am very encouraged by today's news," said Borge Brende, the foreign minister of Norway, which helped fund the trial. This trial vaccine ought to be embraced and welcomed by everybody in Cameroon. After all, the other existing vaccines passed through the same trial process and necessary modifications before being used universally today.

The populations of the Centre Region and the North West Regions in particular and Cameroon in general therefore need a lot of Information and Education for Behavioral Change. Counseling, informed consent, and responsible decision-making are of utmost importance in order to come out of such an impasse. Surveillance of diseases of epidemic potential should be ameliorated and uplifted considering the massive presence of fruit bats and wild animals straying in the communities [23][24][25].

RECOMMENDATIONS

- Misconceptions and rumors should be dispelled and managed adequately by all stakeholders involved in vaccination and immunization programmes.
- Safety concerns and lack of perceived need should be addressed with necessary promptitude by the authorities of the Ministry of Public Health to encourage informed uptake of vaccines.

- Immunization programme coordinators may be able to increase sensitization and awareness by tackling practical problems concerning vaccination refusals.
- More complete information about targeted diseases and comprehensive information regarding benefits and drawbacks of the National Immunization Programmes (NIP) should be provided by the vaccination authorities well in advance to the populations in general and parents in particular. To fulfill parents' information needs, NIP information meetings can be organized at Child Welfare Clinics and other settings in different languages including local languages while at the same time ensuring the use of effective communication methods and strategies.
- Providing NIP information material in local languages such as Mungaka, Lamso, Fulani, Pinyin, Douala, Ewondo, Ngemba, Wimbun, Arabic, Pidgin etc and not only in French and English, with easy accessibility is highly recommended. It is of utmost importance to provide information tailored to these parents' needs so as to sustain high vaccination participation, and to ensure complete acceptance of future vaccination campaigns.

A focus on strengthening health communication activities to raise immunization awareness and address concerns of vaccine side effects at community level is essential.

REFERENCES

1. CDC. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. *MMWR* 2006; 55(No. RR-17).
2. CDC. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. *MMWR* 2011;60;13--5.
3. "Tetanus vaccine: WHO position paper" (PDF). *Weekly epidemiological record* 20 (81): 197–208. May 19, 2006.
4. CDC. Training and Education Branch, National Immunization Program. *Epidemiology and Prevention of Vaccine-Preventable Diseases*, W. Atkins, et al, 6th Edition: 61, 2000
5. Report on the Committee of Infectious Diseases, ed 25. Elk Grove Village, IL. American Academy of Pediatrics, 2000.
6. Centers for Disease Control and Prevention (2011). "Tetanus". *Epidemiology and Prevention of Vaccine-Preventable Diseases* (CDC, *Epidemiology and Prevention of Vaccine-Preventable Diseases* (pdf). Washington, D.C: Public Health Foundation. ISBN 0-01-706609-3. Retrieved January 4, 2016.
7. <http://www.cdc.gov/tetanus/about/index.html>
8. Roper, Martha H; Vandelaer, Jos H; Gasse, François L (12 September 2007). "Maternal and neonatal tetanus"(PDF).*The Lancet*. Retrieved 1 September 2015.
9. "Maternal and Neonatal Tetanus Elimination by 2005" UNICEF. Retrieved 17 February 2014.
10. "Tetanus"(PDF). CDC Pink Book. Retrieved 19 January 2014.
11. "Maternal and Neonatal Tetanus Elimination by 2005" UNICEF. November 2000. Retrieved 2007-01-26.
12. "Maternal and Neonatal Tetanus Elimination Initiative"(PDF). Pampers UNICEF 2010 campaign: 2.
13. "Elimination of Maternal and Neonatal Tetanus". UNICEF. Retrieved 17 February 2014.
14. "Uganda announces elimination of Maternal and Neonatal Tetanus". Unicef Media Centre. Retrieved 19 January 2014.
15. "Pampers and UNICEF aim to eliminate maternal and neonatal tetanus in Yemen". AME info.com. March 29, 2011. Retrieved 19 January 2014.
16. "Maternal and Neonatal Tetanus". UNICEF United States Fund. Retrieved 17 February 2014.
17. *MMWR - Human Papillomavirus Vaccination Coverage Among Adolescents, 2007–2013, and Post licensure Vaccine Safety Monitoring, 2006–2014 — United States*.
18. Sarah Boseley Health editor, Friday 31 July 2015 16.44 BST Last modified on Saturday 1 August 2015 00.02 BST.
19. Van Lier EA, Oomen PJ, Giesbers H, Drijfhout IH, de Hoogh PAAM and de Melker HE. Vaccinatiegraad Rijksvaccinatieprogramma Nederland verslagjaar 2012. [Immunization coverage National Immunization Programme in the Netherlands: Year of report 2012] (Report No. 201001001). 2012. <http://www.rivm.nl/bibliotheek/rapporten/201001001.html> website
20. Harmsen IA, Ruiters RAC, Paulussen TGW, Mollema L, Kok G, De Melker HE. Factors that influence vaccination decision-making by parents who visit an anthroposophical child welfare center: A Focus Group Study. *Adv Prev Med*. 2012; 2012:1-7.
21. Paulussen TGW, Hoekstra F, Lanting CI, Buijs GB, Hirasings RA. Determinants of Dutch parents' decisions to vaccinate their child. *Vaccine*. 2006; 24:644-51.
22. Blume S. Anti-vaccination movements and their interpretations. *Soc Sci Med*. 2006; 62:628-42.
23. Austvoll-Dahlgren A, Helseth S. What informs parents' decision-making about childhood vaccinations? *J Adv Nurs*. 2010; 66:2421-30.
24. Woonink F. Objections against vaccination: the perspective of those who refuse. *Infectieziekten Bull*. 2009; 20:50-51.
25. Harmsen IA, Ruiters RAC, Paulussen TGW, Mollema L, Kok G, De Melker HE. Factors that influence vaccination decision-making by parents who visit an anthroposophical child welfare center: A Focus Group Study. *Adv Prev Med*. 2012; 2012:1-7.
26. Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, et al. Emergence of Zaire Ebola Virus Disease in Guinea - Preliminary Report. *N Engl J Med*. Apr 16 2014.
27. Centers for Disease Control and Prevention (CDC). 2014 Ebola outbreak in West Africa. Center for Disease Control and Prevention (CDC). Available at <http://www.cdc.gov/vhf/ebola/outbreaks/guinea/>. Accessed September 6, 2014.
28. Roddy P, Howard N, Van Kerkhove MD, Lutwama J, Wamala J, Yoti Z, et al. Clinical manifestations and case management of Ebola haemorrhagic fever caused by a newly identified virus strain, Bundibugyo, Uganda, 2007-2008. *PLoS One*. 2012;7(12):e5298.
29. Williams Keywords: Vaccination; Immunization; Miscon identified virus strain, Forster A, Marlow L, Waller J. Attitudes towards human papillomavirus vaccination: a qualitative study of vaccinated and unvaccinated girls aged 17–18 years. *J Fam Plann Reprod Health Care*. 2011;37(1):22–5.